The Elm | 2021 Founders Week Award Winners Announced umaryland.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from umaryland.edu Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NEW YORK, Feb. 18, 2021 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it intends to expand the development of the HT-003 active pharmaceutical ingredient (API) to pursue a new indication for the treatment of inflammatory bowel diseases (IBDs), including Crohn s disease and ulcerative colitis. Hoth executed an option agreement with Isoprene Pharmaceuticals, Inc. ( Isoprene ) to investigate the potential for the HT-003 API as an IBD therapeutic. Isoprene is a University of Maryland, Baltimore New Venture Initiative start-up company.
IBDs represent a large health burden in the United States, affecting approximately 3 million adults age 18 years and older that continues to increase each year.